As an Exhibitor, you will gain high visibility among top leaders in the Life Sciences sector. Ideally located at the focal point of the event, the Exhibition area enables participants to access key information, expand their network, highlight their skills, services and innovations and enhance their visibility.
BioFIT 2018 will host the 4th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative, on the 4th and 5th of December 2018, in Lille.
Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).
By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.
About SIMV
While being the organiser of this meeting, the SIMV intends to federate research actors by actively contributing to meet the needs in animal health innovation. In particular, enhanced research is needed to supplement and renew the therapeutic arsenal for the treatment of infectious diseases and therefore research and innovation on this topic should be promoted.
Many thanks to LFB for joining BioFIT 2018 as a Contributing Sponsor!
Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for diseases that are always serious and often rare. The LFB Group is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are medicinal products derived from living organisms in three major fields of therapy: immunology, haemostasis and intensive care.
The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.
LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in nearly 60 countries. Over 2000 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients. Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.
Join key BioFIT 2018 sponsors such as Bayer, Roche, MSD, Boehringer Ingelheim, Pfizer and VIB, to have the opportunity to:
Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale andbe recognisedas a key innovative actor
Show your expertise thanks to specific communication tools
They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.
#BioFIT2018 preliminary programme is now available
In this brochure, you will find all the information you need about the 7th edition of the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation in the field of Life Sciences.
Many thanks to Pfizer for joining BioFIT 2018 as a Bronze Sponsor!
Pfizer is a leading research-based biopharmaceutical company. They apply science and their global resources to deliver innovative therapies that extend and significantly improve lives. They make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands.
Pfizer teams work in developed and emerging markets to treat, cure and eradicate life-threatening conditions and challenge some of the most feared diseases of our time. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Join key BioFIT 2018 sponsors such as Bayer,Roche, MSD, Boehringer Ingelheim and LFB, to have the opportunity to:
Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibilityon an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools
They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.
Conference Insight – Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?
4 Dec 2018 9:30 – 11:00 am
The seed investment market is composed of actors with really diverse degree of specialisation (from totally agnostic and multi-sectorial to pure players in specific therapeutic indications). Do the most specialised funds attract more generalist ones in the financing rounds? What is the respective importance today in the amount of seed investment of the multi-sectorial funds, the 100% healthcare orientated funds and the pure players in the biotech sector.[/vc_column_text][vc_column_text]They will share their experience:
Jan Adams, Managing Director, EMBL Ventures (DE)
Jonathan Tobin, Investment Director, Arix Bioscience (UK)
Discover the new speakers that will share their vision at BioFIT 2018:
Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.
Alain Chevallier Life Sciences Partner Truffle Capital
Marco A. Chacon Assistant Vice President of Industry Alliances University of Maryland Baltimore
Rodolphe Besserve Head SuFT Advisory, Start-up & French Techs Société Générale Corporate Investments and Banking
When addressing the contractual relationships between a university and its spin-off: What are the issues regarding equity, royalties and research income? How do VCs, academic institutions, spin-off management and human resources management of the university interact? What are the main conflicts of interests that can arise from people holding dual positions, in the university and in the start-up?
They will share their experiences:
Adrian Ibrahim, Head of technology Transfer, Wellcome Sanger Institute (UK)
Caroline Barelle, CEO, Elasmogen (UK)
Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
Steven J. Klein, Vice President, Business Development IRICoR – Institute for Research in Immunology and Cancer – Commercialization of Research (CA)
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
BioFIT 2018 will host the 4th edition of the “R&D dating for Animal Health and Innovation” business convention, at the French association for the animal healthcare industry (SIMV)’s initiative, on the 4th and 5th of December 2018, in Lille.
